Sanofi SA says its net profit soared 26.3 percent in the fourth quarter thanks to a lower charges against its Lemtrada multiple sclerosis treatment. The world’s third-largest drugmaker by sales reported net profit of 1.34 billion in the period.

Click here to read original article